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Abstract
Lithium is an anti-psychotic that has been shown to prevent the hyperphosphorylation of tau protein through the inhibition
of glycogen-synthase kinase 3-beta (GSK3b). We recently developed a mouse model that progresses from amyloid
pathology to tau pathology and neurodegeneration due to the genetic deletion of NOS2 in an APP transgenic mouse; the
APPSwDI/NOS22/2 mouse. Because this mouse develops tau pathology, amyloid pathology and neuronal loss we were
interested in the effect anti-tau therapy would have on amyloid pathology, learning and memory. We administered lithium
in the diets of APPSwDI/NOS22/2 mice for a period of eight months, followed by water maze testing at 12 months of age,
immediately prior to sacrifice. We found that lithium significantly lowered hyperphosphorylated tau levels as measured by
Western blot and immunocytochemistry. However, we found no apparent neuroprotection, no effect on spatial memory
deficits and an increase in histological amyloid deposition. Ab levels measured biochemically were unaltered. We also found
that lithium significantly altered the neuroinflammatory phenotype of the brain, resulting in enhanced alternative
inflammatory response while concurrently lowering the classical inflammatory response. Our data suggest that lithium may
be beneficial for the treatment of tauopathies but may not be beneficial for the treatment of Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative
disorder characterized clinically by an advancing cognitive
decline. Pathologically, AD is identified by the presence of
extracellular amyloid plaques composed of aggregated Aß peptides
and intracellular neurofibrillary tangles (NFTs) composed of
hyperphosphorylated, aggregated tau protein [1]. Both amyloid
plaques and neurofibrillary tangles are the targets of disease-
modifying therapy development for the treatment of AD.
Tau protein is a microtubule associated protein that is involved
in the stabilization of microtubules in a phosphorylation
dependent manner [2]. Abnormal and/or excessive phosphoryla-
tion of tau protein leads to its permanent dissociation from the
microtubule, redistribution to the cell soma and aggregation
leading to the formation of an insoluble NFT. While NFTs are
pathological hallmarks of AD, they also characterize other
tauopathies such as progressive supranuclear palsy (PSP) and
frontotemporal dementia (FTD) [3]. The abnormal phosphoryla-
tion of tau is thought to result from disruption of the kinase-
phosphatase systems. Therefore, inhibition of kinases has been one
target for the reduction of hyperphosphorylated tau, and therefore
NFTs [4].
Lithium is an antipsychotic medication that has been shown to
inhibit glycogen-synthase kinase 3-beta (GSK3b); a key kinase for
the phosphorylation of tau [5]. We recently developed a mouse
model for the study of AD that develops tau pathology in addition
to amyloid pathology [6]. This mouse develops extensive amyloid
deposition, hyperphosphorylated tau and neuronal loss by 12
months of age. We have previously shown that targeting the
amyloid pathology using anti-Ab immunotherapy results in
amelioration of not only the amyloid pathology but also the tau
pathology, neuronal loss and improvement in learning and
memory [7]. Our goal in the current study was to determine
what impact targeting the tau pathology using lithium would have
on the amyloid pathology, neuronal loss, learning and memory.
Our findings replicate those of Noble et al who showed reductions
in hyperphosphorylated tau in response to lithium treatment in
mice expressing the P301L human tau mutation [8]. However, we
found that lithium had no impact on Ab levels and, in fact,
increased the density of amyloid deposits. We believe that this may
be due to an altered inflammatory state of the brain resulting from
the lithium treatment; an effect separate from the action at the
GSK3b site.
Results
Radial-arm water maze testing showed that non-transgenic,
wildtype (WT) and NOS22/2 mice aged 12 months learned the
task as is evidenced by the decline in number of errors over the two
days of testing, ending with a mean of less than 1 error at the end
of day 2 (figure 1). Importantly, all mice, transgenic and non-
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APPSwDI/NOS22/2 mice aged 12 months were significantly
impaired in the radial-arm water maze as previously shown ([6]
figure 1). As can be seen in figure 1, treatment of APPSwDI/
NOS22/2 mice with lithium also resulted in impaired memory
and learning when compared to either the non-transgenic or
NOS22/2 mice but the number of errors was not statistically
different from untreated APPSwDI/NOS22/2 mice. Thus,
treatment of mice with lithium did not result in significant changes
in memory as measured by the radial-arm water maze.
Since lithium has been associated with reduced tau hyperpho-
sphorylation and subsequent aggregation we assessed tau phos-
phorylation by semi-quantitative Western blot. We observed a
reduced signal for both AT8 (which recognizes tau phosphoryla-
tion at Ser202/Thr205) and AT180 (which recognizes tau
phosphorylation at Thr231) (figure 2A). Both sites are associated
with pathological phosphorylation in AD and other tauopathies.
Densitometric quantification of the band intensity when normal-
ized to ß-actin showed an approximate 35% reduction in tau
hyperphosphrylation for both AT8 and AT180 (figure 2B).
Immunohistochemistry for AT8 revealed a noticeable reduction
in immunopositive neurons in the cortical regions of the brain. A
representative example of stain intensity in shown in Figure 2 for
untreated (2C_) vs lithium treated mice (2D) mice.
To determine the effects of lithium on Ab, we assessed Ab by
both biochemical and immunohistochemical methods. As can be
seen in figures 3A and B we did not observe significant differences
in soluble or insoluble Ab38, Ab40 or Ab42 resulting from the
lithium treatment. We did, however, observe a significant increase
in the amount of Ab immunohistochemical staining. This was
evident throughout the brain but most noticeable in the
hippocampus (figure 3C and D), especially the dentate gyrus
region (figure 3E and F). When we quantified the percent area
occupied by immunoreactive product in both the frontal cortex
and hippocampus we found a statistically significant 30% increase
in both regions (figure 3G).
We have previously shown that the APPSwDI/NOS22/2
mouse develops significant neuronal loss by 12 months of age [6].
We have also shown that anti-Ab immunotherapy ameliorates this
neuronal loss. We performed Nissl staining on serial sections and
performed stereological neuron counts on the CA3 region of the
hippocampus and the subiculum; the two regions previously found
to show the most dramatic neuronal loss in the APPSwDI/
NOS22/2 mice [6]. We found that the APPSwDI/NOS22/2
mice receiving control diet showed a significant neuronal loss
comparable to that previously reported in 12 month old mice
(figure 4B, E and G). Interestingly, we observed the same degree of
neuronal loss in APPSwDI/NOS22/2 mice receiving the lithium
supplemented diet, indicating that lithium treatment did not
prevent neuronal loss in the APPSwDI/NOS22/2 mice
(figure 4C, F and G).
To determine whether lithium had an influence on the
microglial population we performed immunocytochemistry for
CD11b and CD45. CD11b is a standard marker for all states of
microglial cells that increases in intensity with activation [9].
Figure 1. Lithium does not improve outcomes on the radial-
arm water maze spatial memory task. APPSwDI/NOS22/2 mice
receiving either control diet (N=8, 4 male and 4 female) or lithium
supplemented diet (N=11, 4 female and 7 male), NOS22/2 (N=7, 3
female and 4 male) and wildtype mice (N=7, 3 female and 4 male) aged
12 months were tested on the two-day radial-arm water maze task.
Data are shown as mean number of errors per block number. Each
block comprises three trials. * indicates P,0.05, ** indicates P,0.01 for
both the APPSwDI/NOS22/2 treatment groups when compared to
NOS22/2 and wildtype mice for each block number.
doi:10.1371/journal.pone.0031993.g001
Figure 2. Lithium treatment reduces the levels of abnormally
phosphorylated tau protein in APPSwDI/NOS22/2 mice. Panel
A shows representative Western blot images for AT8, AT180 and ß-actin
for APPSwDI/NOS22/2 mice receiving either lithium diet (L) or control
diet (C). Panel B shows the relative quantification of the band intensity
for AT8 and AT180 normalized to the ß-actin band. N=11 lithium
treated mice, N=8 control treated mice. ** indicates P,0.01 when
compared to control treated mice. Panels C and D show immunocy-
tochemistry for AT8 in the frontal cortex region of APPSwDI/NOS2-/
mice receiving control diet (C) or lithium supplemented diet (D) for 8
months. Scale bar in D for C and D=50 mm.
doi:10.1371/journal.pone.0031993.g002
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brain but is expressed upon activation [9]. We observed CD11b
staining throughout the brain, with increased intensity in the
subiculum and dentate gyrus of APPSwDI/NOS22/2 mice,
which corresponds to the regions of the most intense amyloid
deposition (figure 5A). Lithium treatment did not alter the pattern
or observed intensity of the CD11b staining (figure 5B). Quan-
tification of percent area occupied by positive immunostain
showed no significant difference between APPSwDI/NOS22/2
mice receiving either control or lithium supplemented diet
(figure 5C). In contrast to CD11b, we found that lithium treatment
decreased the amount of CD45 immunostaining in the brain and
the intensity of the staining (figure 5D and E). Quantification of
the percent area occupied by positive immunostain showed a
significant decrease in the amount of CD45 staining in both the
frontal cortex and hippocampus (figure 5F).
To further characterize the inflammatory changes that might
occur as a result of the lithium treatment we performed
quantitative real-time RT-PCR for genes associated with classical
and alternative inflammatory responses. We have previously
shown that transgenic mice show diverse inflammatory responses
and anti-Ab immunotherapy significantly alters these responses
[10]. We found that untreated APPSwDI/NOS22/2 mice show
significant increases in mRNA for classical inflammatory genes
interleukin 1b (IL-1b), interleukin 6 (IL-6), macrophage receptor
with collagenous structure (MARCO), tumor necrosis factor a
(TNFa) and TNFa receptor 1 (TNFaR1) (figure 6A). Interestingly,
lithium treatment significantly reduced the expression of each of
these genes to levels observed in wildtype mice (figure 6A). While
lithium treatment significantly lowered classical inflammatory gene
expression, it increased alternative gene expression. We found that
APPSwDI/NOS22/2 mice on a normal diet showed significant-
ly elevated expression of alternative activation genes arginase 1
(ARG1), YM1, IL-1Ra (the IL-1 receptor antagonist), mannose
receptor C1 (MRC1) and transforming growth factor-b1 (TGFb1)
compared to wildtype mice (figure 6B) Interestingly, in contrast to
the effect lithium had on classical genes, we found that lithium
further increased the mRNA expression of some alternative
inflammation genes in APPSwDI/NOS22/2 mice (figure 6B).
With respect to ARG1, YM1 and IL-1Ra there was a statistically
significant increase in lithium treated mice compared to untreated
APPSwDI/NOS22/2 mice (figure 6B).
Discussion
The effect of lithium to significantly lower hyperphosphoryla-
tion of tau protein in mouse models of tauopathies was clearly
shown by Noble et al [8] who linked the effect of lithium on tau to
its action as an inhibitor of GSK3b [5]. More recently, it was also
shown that lithium increased Hsp70 [11] Hsp70 has been shown
to be important in the ubiquitination and subsequent degradation
of tau protein [12,13]. The published data on the beneficial effects
Figure 3. Lithium treatment of APPSwDI/NOS22/2 mice does not change Ab levels but does increase Ab deposition. Panels A and B
show biochemical ELISA measurement of Ab38, 40 and 42 in soluble (A) and insoluble (B) protein extracts. Panels C–F show representative images of
the whole hippocampus at 406magnification (C and D) and the dentate gyrus of the hippocampus at 1006magnification (E and F) of APPSwDI/
NOS22/2 mice receiving control diet (C and E) or lithium diet (D and F). Scale bar in D for C and D=120 mm, scale bar in F for E and F=50 mm. Panel
G shows quantification of percent area occupied by positive stain for mice receiving control diet (N=8) or lithium diet (N=11) for 8 months.
* indicates P,0.05, ** indicates P,0.01 when compared to APPSwDI/NOS22/2 mice receiving control diet.
doi:10.1371/journal.pone.0031993.g003
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several clinical studies of lithium as a potential treatment for
Alzheimer’s disease [14,15].
We recently developed a mouse model of Alzheimer’s disease
that develops amyloid pathology as well as endogenous mouse tau
pathology and significant neurodegeneration [6]. Treatment of the
APPSwDI/NOS22/2 mouse model with anti-Ab therapies was
subsequently shown to lower not only amyloid pathology but also
tau pathology as well as to reduce neuronal loss [7]. We were
particularly interested to determine whether a therapy targeting
tau would have similar effects on amyloid pathology and
neurodegeneration so we elected to treat our mice with lithium
supplemented diet. Mice were treated for 8 months with either
lithium supplemented, or control diet beginning at 4 months of
age. While our data show a reduction in hyperphosphorylated tau
levels on lithium treated APPSwDI/NOS22/2 mice, spatial
memory of the mice remained significantly impaired. In addition,
neurodegeneration was not blocked by lithium and amyloid
deposition was increased. These data are similar to studies on the
3XTg transgenic mouse model that expresses mutated human
APP, PS1 and mutated human tau where lithium treatment was
also associated with reduced tau pathology but no change in either
Ab levels or memory [16]. Our current study expands on the
findings of Caccamo et al by showing that lithium also influences
neuroinflammation. Treatment of APPSwDI/NOS22/2 mice
with lithium altered the inflammatory state of the brain by
reducing CD45 positive microglia, lowering classical inflammatory
markers and increasing alternative inflammatory markers.
GSK3b is a serine/threonine protein kinase that has been
shown to be involved in the phosphorylation of tau protein. In
particular, GSK3b has been linked to the abnormal phosphory-
lation of tau in AD, and other tauopathies [17,18]. While lithium
has been shown to prevent the hyperphosphorylation of tau in
mouse models expressing mutant human tau, we report here that
lithium also significantly reduces abnormal tau phosphorylation in
a mouse model that develops tau pathology in normal, native
mouse tau. This is an important finding since mutations of human
tau are linked to tauopathies and have not yet been shown to occur
Figure 4. Lithium treatment does not alter neuronal loss in the APPSwDI/NOS22/2 mice. Panels A–F show Nissl staining for wildtype (A
and D), APPSwDI/NOS22/2 mice receiving control diet (B and E) and APPSwDI/NOS22/2 mice receiving lithium diet (C and F). Panels A–C show the
whole hippocampus at 406 magnification (scale bar in A for A–C=120 mm). Panels D–F show the CA3 region of the hippocampus at 1006
magnification (scale bar in D for D–F=50 mm). Panel G shows stereological counts of neuron number in the subiculum and CA3 of wildtype mice and
APPSwDI/NOS22/2 mice receiving either control diet or lithium diet. ** indicates P,0.01 compared to wildtype mice.
doi:10.1371/journal.pone.0031993.g004
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abnormal phosphorylation of normal tau as well as mutant tau
further reinforces this approach for the treatment of tauopathies.
Despite these beneficial effects of lithium treatment on tau,
lithium did not alter total brain levels of soluble and insoluble
Ab38, 40 and 42 and did not protect the neurons from
degeneration. Thus, the tau-lowering action of lithium appears
to be independent of Abeta and is unlikely to have altered the
production or clearance kinetics of the Ab peptides. Interestingly,
the effect of lithium to increase observable amyloid deposition in
the brain suggests that lithium may directly or indirectly alter the
environment of the brain to promote the deposition of Ab.
Neuroinflammation is known to be present in the AD brain and
has been hypothesized to be intimately involved in the control of
AD pathologies [19]. There are numerous studies reporting
conflicting effects of inflammation on amyloid pathology. Lipo-
polysaccharide (LPS) has been shown to both reduce [20,21] and
increase [22] amyloid deposition in APP transgenic mice. We have
previously shown that anti-Ab immunotherapy increases the pro-
inflammatory phenotype of microglia, which appears to be at least
partially responsible for the reductions in amyloid deposition
[23,24]. In the human clinical trials for immunotherapy there is
also evidence that microglia are involved in the clearance of
amyloid deposits [25]. More recently, we have shown that
immunotherapy switches the inflammatory state of the brain
away from an alternative inflammatory state while concurrently
driving a classical inflammation [10]. In contrast to immunother-
apy, we show here that lithium significantly increased gene
markers characteristic of alternative activation and acquired
deactivation immune states, both of which are associated with
immunosuppression [26]. The concomitant loss of classical
activation gene markers, further strengthens a functional pheno-
typic change away from removal of Abeta towards one of amyloid
deposition [10]. Although the exact functional role of CD45
expression has not been well defined, the loss of CD45
immunoreactivity may also signal a switch to an immunosuppres-
sive state.
Lithium is known to influence inflammation. Rapaport and
Manji showed that lithium results in an increase in Th2 cytokines
IL-4 and IL-10 along with a decrease in the Th1 cytokines IFNc
and IL-2 in an ex vivo assay on whole blood cultures [27]. Further
supporting the effect of lithium on neuroinflammation is the recent
finding that lithium reduced microglial activation and inhibited
the production of classical inflammatory cytokines IL-1b and
MCP-1 in a rat model of hypoxia-ischemia [28]. Our data shows
similar effects, where classical inflammatory marker gene expres-
sion is significantly reduced following lithium treatment and
alternative inflammatory marker gene expression is significantly
increased. Since IL-4 and IL-10 are critical mediators of the
alternative inflammatory response we can conclude that the
findings of Rapaport and Manji expand to the brain, where Th1
cytokines are reduced and Th2 cytokines are elevated by lithium.
Alternative inflammatory genes are often associated with wound
repair and matrix remodeling. In fact, arginase 1 has been
associated with the onset and progression of fibrosis in cystic
fibrosis [29] and schistosoma infection [30]. YM1, also known as
chitinase-3-like-3 (Chi3l3) is associated with matrix remodeling
during parasitic infections [31] and in the development of
dermatitis [32]. We hypothesize that the pro-fibrotic properties
of the alternative inflammatory mediators promotes the fibrillo-
genesis of Ab in the brain resulting in increased deposition of Ab.
The exacerbation of alternative inflammation in the presence of
reduced classical inflammation by lithium treatment in the current
study would support this hypothesis.
In summary, we find that lithium treatment of the APPSwDI/
NOS22/2 mouse results in decreased tau hyperphosphorylation,
increased amyloid deposition, altered neuroinflammation and no
change in neurodegeneration or memory.
Figure 5. Microglial activation is reduced following lithium treatment. Panels A and B show CD11b immunocytochemistry in the
hippocampus of APPSwDI/NOS22/2 mice receiving either control diet (A) or lithium diet (B) for 8 months. Scale bar in panel A for A and B=120 mm.
Panel C shows quantification of the percent area occupied by positive stain for CD11b in the frontal cortex and hippocampus. Panels D and E show
CD45 immunocytochemistry in the hippocampus of APPSwDI/NOS22/2 mice receiving either control diet (D) or lithium diet (E) for 8 months. Scale
bar in panel D for D and E=120 mm. Panel F shows quantification of the percent area occupied by positive stain for CD45 in the frontal cortex and
hippocampus. * indicates P,0.05 and ** indicates P,0.01 when compared to APSPwDI/NOS22/2 mice receiving control diet.
doi:10.1371/journal.pone.0031993.g005
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Transgenic mice and treatments
The study was approved by the Duke University Institutional
Animal Care and Use Committee and conformed to the National
Institutes of Health Guide for the Care and Use of Animals in
Research. The APPSwDI/NOS22/2 mice (produced by
crossing APPSwDI mice [33] with NOS22/2 mice [34]) have
been described previously [6]. 19 mice aged four months were
assigned to one of two groups, either control diet (N=8) or
lithium diet (N=11). Both the control diet and lithium diet were
obtained from TestDiet (a division of LabDiet Purina-Mills
International, Land O’ Lakes FL). Lithium diet was formulated at
2 g lithium/kg diet to achieve a dose of 333 mg/kg/day as
described previously [35]. Diet was replaced on the cage top
weekly and mice were weighed weekly. No statistically significant
change in body weight occurred throughout the duration of the
study for either treatment group.
Radial-arm water maze
Mice (12 months old) were tested for memory and learning two
days prior to sacrifice using the two-day radial-arm water maze as
described in detail previously [36]. Briefly, a six-arm maze is
submerged in a pool of water, and a platform is placed at the end
of one arm. The mouse receives 15 trials per day for 2 days. The
mouse begins each trial in a different arm while the arm
containing the platform remains the same. The numbers of errors
(incorrect arm entries) are counted over a one-minute period. The
errors are averaged over three trials, resulting in 10 blocks for the
two-day period (blocks 1–5 are day 1 while blocks 6–10 are day 2).
Non-transgenic (N=7) and NOS22/2 mice (N=7) aged 12
months were also assessed in the radial-arm water maze to
determine transgene-dependent behavior changes.
Tissue Processing and histology
After injection with a lethal dose of ketamine the mice were
perfused intracardially with 25 ml normal saline. Brains were
rapidly removed and bisected in the mid-sagittal plane. The left
half was immersion fixed in 4% paraformaldehyde, while the right
half was snap-frozen in liquid nitrogen and stored at 280uC. The
left hemibrain was passed through a series of 10, 20 and 30%
sucrose solutions as cryoprotection and 25 mm frozen horizontal
sections were collected using a sliding microtome and a freezing
stage as described previously [37]. The frozen right hemibrain was
pulverized using a mortar and pestle with liquid nitrogen and the
brain powder stored at 280uC.
Eight 25 mm sections equally spaced 600 mm apart were
selected for free floating immunohistochemistry for Ab (rabbit
polyclonal anti-Ab N terminal, Invitrogen, Carlsbad, CA.
1:3,000), neuN (Mouse monoclonal, Millipore, Temecula, CA.
1:3,000), PHF-tau (AT8, mouse monoclonal for PHF-tau
recognizing phosphorylated Ser202 in tau, Thermo Scientific,
Rockford, IL. 1:300), CD45 (Rat monoclonal, Thermo Scientific,
Rockford IL. 1:3,000) and CD11b (Rat monoclonal, AbD Serotec,
Raleigh NC. 1:3,000). The method for free-floating immunohis-
tochemistry has been described previously [6]. Additionally, eight
25 mm sections equally spaced 600 mm apart were selected,
mounted on slides and stained in a 0.5% Cresyl violet solution
(Sigma-Aldrich, St Louis, MO) for 5 minutes at room tempera-
ture. The sections were then differentiated in 70% and 95%
ethanol solutions before being coverslipped.
Immunohistochemical product was quantified by assessing
percent area occupied by positive stain using the Nikon Elements
BR software package (Nikon, Melville NY). Briefly, images were
collected on a Nikon Eclipse 90i upright microscope equipped
with a Nikon DS-Ri1 digital camera. Specific landmarks on the
tissue section were used to ensure the correct regions were
examined. Fields of the frontal cortex and hippocampus were
localized using 1006magnification followed by image collection at
2006magnification. Representative images were used to establish
thresholds using Hue, Saturation and Intensity (HSI) values. The
threshold file was saved and then applied to all images from all
samples of a given immunostain to yield individual percent area
occupied values for each image. Approximately six images of
frontal cortex and four images of the hippocampus were assessed
for each animal.
Quantitative real-time RT-PCR
RNA was extracted from approximately 40 mg frozen pulver-
ized tissue using the RNeasy tissue kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. RNA was quantified
using the nanodrop spectrophotometer (Thermo Scientific, Rock-
ford IL) and cDNA produced using the cDNA High Capacity kit
Figure 6. Lithium significantly alters the inflammatory state of
the APPSwDI/NOS22/2 mouse brain. Panels A and B show relative
gene expression changes of classical inflammatory genes (A) and
alternative inflammatory genes (B) in wildtype mice and APPSwDI/
NOS22/2 mice receiving either control or lithium diet. Data are shown
as fold change compared to the mean of the wildtype mice. ** indicates
P,0.01 when compared to wildtype expression. # indicates P,0.05
when compared to APPSwDI/NOS22/2 mice receiving control diet.
doi:10.1371/journal.pone.0031993.g006
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turer’s instructions. Real-time PCR was performed using the
TaqMan Gene Expression assay kit (Applied Biosystems, Foster
City CA) according to the manufacturer’s instructions and as
previously described [10]. The genes examined are summarized in
table 1; all were normalized to 18S rRNA. We determined fold-
change compared to non-transgenic mice using the 2
(2delta delta Ct)
method [38].
Western Blot
Approximately 60 mg of the brain powder was homogenized
and protein lysates were prepared in M-per lysis buffer (Thermo
Scientific, Rockford, IL) containing 1% complete protease/
phosphatase inhibitor (Thermo Scientific, Rockford IL). Protein
concentrations were assessed using the BCA protein assay kit
(Thermo Scientific, Rockford, IL), according to manufacturer’s
instructions. 15 mg protein from each lysate was run on a
denaturing 4–20% SDS-PAGE gel. The gel was transferred onto
a PVDF membrane using the iBlot system (Invitrogen, Carlsbad
CA), and Western blots were performed for PFH Tau AT8
(Thermo Scientific, Rockford, IL 1:500) and AT180 (Thermo
Scientific, Rockford IL 1:1000). The blots were stripped using 56
New Blot Nitro Stripping Buffer (Licor, Lincoln NE) and re-
probed using the above protocol for with ß-actin as loading
control. Semi-quantitative densitometry analysis was performed
using the Odyssey Imaging Software (Licor, Lincoln, NE).
Individual densitometry values were normalized to the b-actin
densitometry value on the same blot.
ELISA
For ELISA measurement of Ab we performed a two step
protein extraction. 150 mg brain powder was first extracted in
250 ml PBS containing 1% complete protease/phosphatase
inhibitor (Thermo Scientific, Rockford IL). The homogenate was
centrifuged at 16,0006ga t4 uC for 30 minutes. The supernatant
was removed and became the ‘‘soluble’’ extract. The resulting
pellet was then homogenized in 100 ml 70% formic acid and
centrifuged at 16,0006ga t4 uC for 30 minutes. The supernatant
was removed, neutralized 1:20 with 1 M Tris-HCl and became
the ‘‘insoluble’’ extract. Protein concentration for both the soluble
and insoluble extracts was determined using the BCA protein
assay according to manufacturer’s instructions. We used the Meso-
Scale Discovery multiplex ELISA system to measure soluble and
insoluble Ab38, Ab40 and Ab42 (MSD, Gaithersburg MD).
ELISA kits were run according to the manufacturer’s instructions.
Stereological analysis
Neurons that were positive for cresyl violet were counted in the
cornu ammonis 3 (CA3) and the subiculum using the optical
fractionator method of stereological counting (West et al., 1991)
and the Olympus CAST 1 stereology system (Olympus, Center
Valley PA) connected to an upright Olympus microscope. The
regions of interests (ROI) were defined using specific landmarks
within the hippocampus to maintain consistency. A grid was
placed randomly over the region of interest slated for counting. At
regularly predetermined positions of the grid, cells were counted
within three-dimensional optical disectors. Within each dissector, a
1 mm guard distance from the top and bottom of the section
surface was excluded. Section thickness was measured regularly on
all collected sections to estimate the mean section thickness for
each animal after tissue processing and averaged 14.64 mm6
0.29 mm for all sections analyzed. The total number of neurons
was calculated using the equation:
N~Q|1=ssf|1=asf|1=hsf
Where N is total neuron number, Q is the number of neurons
counted, ssf is section sampling fraction, asf is the area sampling
fraction and hsf is the height.
Statistics
The significance of genotype- and treatment-specific behavioral
changes were analyzed by the unpaired Student’s t test or two-way
ANOVA. All immunohistochemical, stereological, ELISA, West-
ern blot and qRT-PCR data were analyzed by one-way ANOVA.
The statistical analysis software JMP (Version 9, SAS, Cary NC)
was used for all statistical analyses with p,0.05 judged as
significant. All graphs were made using Graphpad Prism 4
(GraphPad, San Diego, CA).
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